News

Copycats attack Abbott's Humira
Enlarge image

BusinessSwitzerlandGermanyMalta

Copycats attack Abbott's Humira

31.10.2012 - With AET Biotech Ltd. and BioXpress SA, two new players join the queue of Humira copycats.

The two partners pool their expertise in the manufacturing of biologicals and in development and marketing. The TNF-alpha blocker is a promising target with projected global sales of more US$9bn this year. Malta-based AET BioTech Ltd. is the biosimilars operation of German generic drugs firm Alfred E. Tiefenbacher GmbH & Co. KG in Hamburg. BioXpress S.A. is a Swiss biotech focused on the development of monoclonal antibody biosimilars.

The firms aim to jointly develop the biosimilar to registration, based on BioXpress expression technology. AET will shoulder commercialisation of the resulting antibody and will, in addition, provide further investment in terms of committed long-term financing.
The Humira patent runs out in 2016. However, Abbott is trying to prevent biosimilar competition by legal action. Furthermore, larger players like Boehringer Ingelheim are already developing Humira follow-on biologics. Humira has an interesting history. Originally the drug was developed by German BASF AG who sold its pharma business to Abbott.

© eurobiotechnews.eu/pd

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M and ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

MandAFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR300.0%
  • SANTHERA (CH)69.30 CHF103.8%
  • ADDEX (CH)4.07 CHF82.5%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • HYBRIGENICS (F)1.72 EUR-34.4%
  • PROSENSA (NL)9.24 USD-24.4%

TOP

  • SANTHERA (CH)69.30 CHF3453.8%
  • GW PHARMACEUTICALS (UK)438.00 GBP800.9%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.6%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.8%

No liability assumed, Date: 23.07.2014